Compare GRC & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRC | NUVB |
|---|---|---|
| Founded | 1933 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 1994 | 2020 |
| Metric | GRC | NUVB |
|---|---|---|
| Price | $77.33 | $7.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 156.1K | ★ 5.8M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | 32.03 | ★ 71.56 |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $682,389,000.00 | $62,902,000.00 |
| Revenue This Year | $6.62 | $203.82 |
| Revenue Next Year | $4.66 | $58.18 |
| P/E Ratio | $55.19 | ★ N/A |
| Revenue Growth | 3.44 | ★ 698.96 |
| 52 Week Low | $41.85 | $2.87 |
| 52 Week High | $92.78 | $9.75 |
| Indicator | GRC | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 45.40 | 58.20 |
| Support Level | $75.97 | $5.28 |
| Resistance Level | $81.82 | $8.95 |
| Average True Range (ATR) | 2.42 | 0.37 |
| MACD | -0.38 | 0.02 |
| Stochastic Oscillator | 24.23 | 62.35 |
Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of its revenue from the United States.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.